Session length

1 / 20

Which combination constitutes first-line pharmaceutical therapy for Goodpasture's disease?

High dose corticosteroids + cyclophosphamide + plasmapheresis

Goodpasture's disease is an autoimmune attack where antibodies target the glomerular and alveolar basement membranes, so treatment must both remove the antibodies and stop their production. Plasmapheresis quickly clears circulating anti-GBM antibodies from the bloodstream, while high-dose corticosteroids reduce immune system inflammation, and cyclophosphamide suppresses the production of new antibodies by B cells. This combination directly addresses the ongoing immune attack and helps prevent progression to kidney failure and severe lung bleeding. Other approaches don’t tackle the autoimmune process: ACE inhibitors don’t remove antibodies, anticoagulation isn’t effective for this immune-mediated damage, and dialysis alone manages kidney failure without stopping antibody production or clearing circulating antibodies.

ACE inhibitors alone

Anticoagulation therapy

Dialysis without immunosuppression

Next question

Find the option that is right for you!

All options are one-time payments.

$25.99

30 day premium pass

All the basics to get you started

  • Ad-free experience
  • View your previous attempt history
  • Mobile app access
  • In-depth explanations
  • 30 day premium pass access
$59.99 $171.99 usd

6 month DELUXE pass (most popular)

Everything with the 30 day premium pass FOR 6 MONTHS! & the ultimate digital PDF study guide (BONUS)

  • Everything included in the premium pass
  • $171.99 usd value for $59.99! You save $106!
  • + Access to the ultimate digital PDF study guide
  • + 6 months of premium pass access
  • + Priority support
$15.99 $24.99

Ultimate digital PDF study guide

For those that prefer a more traditional form of learning

  • Available for instant download
  • Available offline
  • Hundreds of practice multiple choice questions
  • Comprehensive content
  • Detailed explanations
Image Description
Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy